A Vaccine Trial for Low Grade Gliomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 1, 2026

Study Completion Date

December 31, 2027

Conditions
Low Grade Glioma
Interventions
BIOLOGICAL

Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC

Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.

Trial Locations (1)

15224

RECRUITING

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Connor's Cure

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

James Felker

OTHER